Exosomal-mediated transfer of APCDD1L-AS1 induces 5-fluorouracil resistance in oral squamous cell carcinoma via miR-1224-5p/nuclear receptor binding SET domain protein 2 (NSD2) axis

被引:19
|
作者
Li, Shen [1 ]
Shi, Zhiyan [1 ]
Fu, Suwei [1 ]
Li, Qingfu [1 ]
Li, Bei [2 ]
Sang, Lixiao [3 ]
Wu, Donghong [1 ]
机构
[1] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Stomatol, Peoples Hosp, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China
[2] Southern Med Univ, Affiliated Xiaolan Hosp, Dept Gastroenterol, Zhongshan 450003, Henan, Peoples R China
[3] Zhengzhou Univ, Dept Gynecol & Obstet, Affiliated Hosp 3, Birth Clin, Zhengzhou 450003, Henan, Peoples R China
关键词
APCDD1L-AS1; 5-fluorouracil; miR-1224-5p; NSD2; oral squamous cell carcinoma; DIHYDROPYRIMIDINE DEHYDROGENASE EXPRESSION; CISPLATIN RESISTANCE; CANCER; PROLIFERATION; RNA; PROGRESSION; PROGNOSIS;
D O I
10.1080/21655979.2021.1979442
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Oral squamous cell carcinoma (OSCC) poses a threat to public health worldwide. LncRNA APCDD1L-AS1 has been reported to participate in tumorigenesis and development of acquired chemoresistance. However, the role of APCDD1L-AS1 in 5-fluorouracil (5-FU) resistance regulation within OSCC is still obscure. In this study, 5-FU-resistant cell models were established with OSCC cell lines (HSC-3 and HN-4). Gene expressions and protein levels were detected by RT-qPCR and Western blotting, respectively. CCK-8, colony forming, and flow cytometry were utilized to measure IC50 value, cell viability, and cell apoptosis of 5-FU-resistant OSCC cells. Dual-luciferase reporter assay and RIP assay were applied to identify the associations between miR-1224-5p and APCDD1L-AS1 or NSD2. Herein, high APCDD1L-AS1 expression was shown in OSCC tissues and cells resistant to 5-FU and related to the worse prognosis of OSCC patients. APCDD1L-AS1 knockdown impaired 5-FU resistance in 5-FU-resistant OSCC cells by reducing IC50 value, suppressing cell viability, and accelerating cell apoptosis. Besides, extracellular APCDD1L-AS1 could be transferred to sensitive cells via exosome incorporation, thereby transmitting 5-FU resistance in OSCC cells. Besides, miR-1224-5p was a molecular target of APCDD1L-AS1 and directly targeted NSD2 in 5-FU-resistant cells. MiR-1224-5p exhibited a much lower level in 5-FU-resistant tissues and increased 5-FU sensitivity in 5-FU-resistant OSCC cells. Moreover, NSD2 upregulation neutralized the influence of blocking APCDD1L-AS1 in HSC-3/5-FU and HN-4/5-FU cells on 5-FU resistance. To sum up, our study demonstrated that exosomal APCDD1L-AS1 conferred resistance to 5-FU in HSC-3/5-FU and HN-4/5-FU cells via the miR-1224-5p/NSD2 axis, thus providing a novel target for OSCC chemoresistance.
引用
收藏
页码:7188 / 7204
页数:17
相关论文
共 4 条
  • [1] MiR-31-5p-ACOX1 Axis Enhances Tumorigenic Fitness in Oral Squamous Cell Carcinoma Via the Promigratory Prostaglandin E2
    Lai, Yi-Hsuan
    Liu, Hsuan
    Chiang, Wei-Fan
    Chen, Ting-Wen
    Chu, Lichieh Julie
    Yu, Jau-Song
    Chen, Shu-Jen
    Chen, Hua-Chien
    Tan, Bertrand Chin-Ming
    THERANOSTICS, 2018, 8 (02): : 486 - 504
  • [2] Circular CDC like kinase 1 suppresses cell apoptosis through miR-18b-5p/Y-box protein 2 axis in oral squamous cell carcinoma
    Guo, Lixin
    Luo, Gang
    Liu, Yingjie
    Xu, Jing
    BIOENGINEERED, 2022, 13 (02) : 4226 - 4234
  • [3] MiR-183-5p inhibits lung squamous cell carcinoma survival through disrupting hypoxia adaptation mediated by HIF-1α/NDUFA4L2 axis
    Han, Peng
    Zhang, Boxiang
    Li, Yixing
    Gao, Rui
    Li, Xinru
    Ren, Hui
    Shi, Puyu
    Zhao, Aomei
    Xue, Jianjun
    Yang, Aimin
    Liang, Yiqian
    ONCOGENE, 2024, : 2821 - 2834
  • [4] Actin filament-associated protein 1-antisense RNA1 promotes the development and invasion of tongue squamous cell carcinoma via the AFAP1-AS1/miR-133a-5p/ZIC2 axis
    Tang, Mingming
    Wu, Hao
    Zhang, Huaiqin
    Xu, Xinjiang
    Jiang, Bin
    Chen, Qingwen
    Wei, Yingze
    Qian, Hongyan
    Han, Liang
    JOURNAL OF GENE MEDICINE, 2024, 26 (01):